T 1747/22 of 12.09.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T174722.20240912
- Date of decision
- 12 September 2024
- Case number
- T 1747/22
- Petition for review of
- -
- Application number
- 15752232.7
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- METHOD FOR PREDICTING RESPONSIVENESS TO CANCER TREATMENT USING p300-INHIBITING COMPOUND
- Applicant name
- National Cancer Center
Daiichi Sankyo Company, Limited - Opponent name
- Cellcentric Limited
- Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 83Rules of procedure of the Boards of Appeal 2020 Art 011Rules of procedure of the Boards of Appeal 2020 Art 016
- Keywords
- Sufficiency of disclosure - (yes)
Obiter dictum and remittal
Remittal to the department of first instance
Remittal - (yes)
Apportionment of costs - (no) - Catchword
- -
- Cited cases
- G 0001/03T 0802/97T 0473/98T 0197/10T 2238/11T 2154/15T 0101/17T 0139/20T 1006/21T 1019/22
- Citing cases
- -
Order
For these reasons it is decided that:
1. The appealed decision is set aside.
2. The case is remitted to the opposition division for further prosecution.
3. The request for apportionment of costs is rejected.